

DR. WILLIAM J. ROBBINS JOINS ANPATH GROUP, INC. BOARD OF DIRECTORS

MOORESVILLE, NC (September 02, 2009) Anpath Group, Inc. (OTCBB: ANPG), announced today that Dr. William Jay Robbins, M.D., F.A.C.P., A.A.H.I.V.S., has joined the Board of Directors.

Dr. Robbins background includes a history of active involvement with infectious disease care, specifically with HIV treatment and immunology. Currently he is a member of the National Board of Directors at the American Academy of HIV Medicine. In 2000, he founded his current practice, Infectious Disease of Central Florida in Orlando, Florida. Dr. Robbins is a member of the National Medical Advisory Board of Aguron Corporation, and is the Florida Chapter President at the American Academy of HIV Medicine.

"We are delighted to welcome a physician and scientist of Dr. Robbins's stature in the medical community to our Board of Directors," stated J. Lloyd Breedlove, President and CEO of Anpath Group. "We believe that his insight and experience with infectious disease as well as his clinical research involvement with some of the pharmaceutical industry's most influential companies will be invaluable while we establish our products and services as the Standard of Practice for safe infection prevention solutions," concluded Mr. Breedlove.

Dr. Robbins is a Principal Investigator for a wide range of clinical research studies with numerous pharmaceutical and biotech companies. He has two decades of clinical trial participation and engages as an expert speaker for Pfizer, GlaxoSmithKline, Gilead Sciences, Roche, and Bohringer-Ingelheim. In addition he has held positions as Clinical Instructor at both NOVA Southeastern University School of Osteopathic Medicine and the Orlando Regional Medical Center.

"I look forward to working with the Board of Directors and Mr. Lloyd Breedlove to move Anpath Group to the next level," stated Dr. Robbins. "I believe the company has an excellent product portfolio, the right management team and a strong commitment for innovation to meet the evolving needs of the infectious disease prevention marketplace and the company's growing global customer-base", said Dr. Robbins.

From 1986-1999, Dr. Robbins founded and was senior physician at Central Florida Infectious Disease, P.A., Prior to that he held Chief of Medicine position at A.M.I. Medical Center in Orlando, Florida. Dr. Robbins has participated in numerous community service organizations specifically focused on HIV/AIDS. He has received many awards and honors including the AMI Medical Center Orlando Physician of the Year - 1989 and Glebeigh Hospital, Orlando, Florida Distinguished Faculty Award Recognition for AIDS victims, and has published numerous scientific papers focused on HIV Medicine.

Dr. Robbins earned his Bachelor of Science degree in biology from Lehigh University (1973) and a Doctor of Medicine degree from the University of the State of New York, Albany, New York (1985) He received residency training from the department of internal medicine at the Lutheran Medical Center in Brooklyn, New York (1981-1983) and completed fellowship training

in infectious diseases at the University of the State of New York - Downstate Medical Center in Brooklyn, New York (1983-1985).

About Anpath Group, Incorporated:

Anpath Group, Inc. (Anpath), through its wholly-owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment. Visit www.anpathgroup.com for more information.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks — both natural and man-made. Visit www.envirosi.com for more information.

Forward Looking Statements:

This release may contain forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA and state registration of Anpath Group's products, its ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no duty to update its outlook or other forward-looking statements as of any future date.

Contact Information:

J. Lloyd Breedlove
President & CEO
Anpath Group, Inc.
Phone: 704.658.3350
Email: jlbreedlove@envirosi.com
Website: www.anpathgroup.com

Investor Relations:

Arthur Douglas & Associates, Inc.
Art Batson
407.478.1120